Baker BROS. Advisors LP Lowers Stake in Structure Therapeutics Inc. Sponsored ADR $GPCR

Baker BROS. Advisors LP lessened its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 7.9% in the fourth quarter, Holdings Channel.com reports. The fund owned 1,432,529 shares of the company’s stock after selling 123,580 shares during the quarter. Structure Therapeutics comprises approximately 0.6% of Baker BROS. Advisors LP’s holdings, making the stock its 26th largest position. Baker BROS. Advisors LP’s holdings in Structure Therapeutics were worth $99,632,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. CWM LLC lifted its stake in shares of Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Structure Therapeutics by 530.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after purchasing an additional 901 shares in the last quarter. State of Wyoming acquired a new position in shares of Structure Therapeutics during the second quarter worth about $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Structure Therapeutics during the fourth quarter worth about $127,000. Finally, Banque Cantonale Vaudoise acquired a new position in shares of Structure Therapeutics during the fourth quarter worth about $205,000. Institutional investors and hedge funds own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

NASDAQ:GPCR opened at $45.00 on Thursday. Structure Therapeutics Inc. Sponsored ADR has a one year low of $15.80 and a one year high of $94.90. The business’s 50-day simple moving average is $43.09 and its 200 day simple moving average is $57.53. The stock has a market cap of $3.20 billion, a price-to-earnings ratio of -51.72 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, equities research analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.64 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. BMO Capital Markets set a $145.00 price objective on Structure Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Wall Street Zen cut Structure Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. William Blair restated an “outperform” rating on shares of Structure Therapeutics in a research note on Monday, March 16th. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 price objective on the stock. Finally, Citizens Jmp reduced their price objective on Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a research note on Friday, February 27th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $106.75.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.